Title: Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer
Abstract: v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation represents the most common oncogenic event in papillary thyroid cancer (PTC) . The value of BRAF mutation in the diagnosis and guiding treatment of PTC has achieved enthusiastic investigation since the initiation and progression of PTC has been correlated with BRAF mutation. However, existing evidence does not suggest BRAF mutation as an independent factor in guiding surgical approach, stratifying recurrence risk, or selecting postoperative radioiodine therapy for PTC patients. Although sorafenib and selumetinib have effectively improved the prognosis of patients with radioactive iodine-refractory PTC, such efficacy is independent of BRAF mutation status.
Key words:
Thyroid neoplasms; Diagnosis; Therapy; BRAF mutation
Publication Year: 2015
Publication Date: 2015-03-25
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot